[{"indications": "Indications\u00a0Parkinson\u2019s\r\ndisease, \n(From Levodopa: British National Formulary)\nLevodopa", "name": "CO-CARELDOPA For use with enteral tube", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.9 Drugs used in parkinsonism and related disorders", "4.9.1 Dopaminergic drugs used in Parkinson\u2019s disease", "Levodopa", "CO-CARELDOPA", "For use with enteral tube"], "cautions": "Cautions\u00a0\n(From Levodopa: British National Formulary)\nCautions\u00a0Levodopa should be used with caution in severe pulmonary or cardiovascular disease (including history of myocardial infarction with residual arrhythmia), psychiatric illness (avoid if severe and discontinue if deterioration), endocrine disorders (including hyperthyroidism, Cushing\u2019s syndrome, diabetes mellitus, osteomalacia, and phaeochromocytoma), and in those with a history of convulsions or peptic ulcer. Levodopa should be used with caution in patients susceptible to angle-closure glaucoma, and in hepatic or renal impairment. Patients should be advised to avoid abrupt withdrawal (risk of neuroleptic malignant syndrome and rhabdomyolysis), and to be aware of the potential for excessive drowsiness and sudden onset of sleep (see Driving); interactions: Appendix 1 (levodopa).", "side-effects": "Side-effects\u00a0\n(From Levodopa: British National Formulary)\nSide-effects\u00a0Side-effects of levodopa include nausea, vomiting, taste disturbances, dry mouth, anorexia, arrhythmias, palpitations, postural hypotension, syncope, drowsiness (see Driving), fatigue, dementia, psychosis, confusion, euphoria, abnormal dreams, insomnia, depression (very rarely with suicidal ideation), anxiety, dizziness, dystonia, dyskinesia, and chorea.Less commonly weight changes, constipation, diarrhoea, hypersalivation, dysphagia, flatulence, hypertension, chest pain, oedema, hoarseness, ataxia, hand tremor, malaise, weakness, muscle cramps, and reddish discoloration of the urine and other body fluids may occur. Rare side-effects include abdominal pain, gastro-intestinal bleeding, duodenal ulcer, dyspepsia, phlebitis, dyspnoea, agitation, paraesthesia, bruxism, trismus, hiccups, neuroleptic malignant syndrome (associated with abrupt withdrawal), convulsions, reduced mental acuity, disorientation, headache, urinary retention, urinary incontinence, priapism, activation of malignant melanoma, leucopenia, haemolytic and non-haemolytic anaemia, thrombocytopenia, agranulocytosis, blurred vision, blepharospasm, diplopia, activation of Horner\u2019s syndrome, pupil dilatation, oculogyric crisis, flushing, alopecia, exanthema, Henoch-Sch\u00f6nlein purpura, and sweating; very rarely angle-closure glaucoma may occur; compulsive behaviour (see Impulse Control Disorders) and false positive tests for urinary ketones have also been reported.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/129431.htm", "doses": ["Expressed as levodopa, initially 100\u00a0mg (with carbidopa\r\n25\u00a0mg) 3 times daily, increased by 50\u2013100\u00a0mg (with carbidopa 12.5\u201325\u00a0mg)\r\ndaily or on alternate days according to response, up to 800\u00a0mg (with\r\ncarbidopa 200\u00a0mg) daily in divided doses", "Alternatively, initially 50\u2013100\u00a0mg (with carbidopa 10\u201312.5\u00a0mg)\r\n3\u20134 times daily, increased by 50\u2013100\u00a0mg daily or on alternate days\r\naccording to response, up to 800\u00a0mg (with carbidopa 80\u2013100\u00a0mg) daily\r\nin divided doses ", "Alternatively, initially 125\u00a0mg (with carbidopa 12.5\u00a0mg, as\r\n\u00bd tablet of co-careldopa 25/250) 1\u20132 times daily, increased by 125\u00a0mg\r\n(with carbidopa 12.5\u00a0mg) daily or on alternate days according to response", "When co-careldopa is used, the total daily dose of carbidopa\r\nshould be at least 70\u00a0mg. A lower dose may not achieve full inhibition\r\nof extracerebral dopa-decarboxylase, with a resultant\r\nincrease in side-effects.", "When transferring patients\r\nfrom another levodopa/dopa-decarboxylase inhibitor preparation, the\r\nprevious preparation should be discontinued at least 12 hours before", "Name[Duodopa\u00ae (Abbott Healthcare)  ] Intestinal gel, co-careldopa 5/20 (carbidopa 5\u00a0mg as monohydrate, levodopa 20\u00a0mg)/mL, net price\r\n100\u00a0mL cassette (for use with Duodopa\u00ae portable\r\npump) = \u00a377.00. \r\n    Label:\r\n    10, 14, counselling, driving, see notes aboveDose\u00a0severe Parkinson\u2019s disease inadequately controlled by\r\nother preparations, consult product literature"], "pregnancy": "Pregnancy\u00a0\n(From Levodopa: British National Formulary)\nPregnancy\u00a0Levodopa should be used with caution in pregnancy\u2014toxicity has occurred in animal studies.Breast-feeding\u00a0Levodopa may suppress lactation. It is present in milk\u2014avoid."}, {"indications": "Indications\u00a0Parkinson\u2019s\r\ndisease, \n(From Levodopa: British National Formulary)\nLevodopa", "name": "CO-CARELDOPA", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.9 Drugs used in parkinsonism and related disorders", "4.9.1 Dopaminergic drugs used in Parkinson\u2019s disease", "Levodopa", "CO-CARELDOPA"], "cautions": "Cautions\u00a0\n(From Levodopa: British National Formulary)\nCautions\u00a0Levodopa should be used with caution in severe pulmonary or cardiovascular disease (including history of myocardial infarction with residual arrhythmia), psychiatric illness (avoid if severe and discontinue if deterioration), endocrine disorders (including hyperthyroidism, Cushing\u2019s syndrome, diabetes mellitus, osteomalacia, and phaeochromocytoma), and in those with a history of convulsions or peptic ulcer. Levodopa should be used with caution in patients susceptible to angle-closure glaucoma, and in hepatic or renal impairment. Patients should be advised to avoid abrupt withdrawal (risk of neuroleptic malignant syndrome and rhabdomyolysis), and to be aware of the potential for excessive drowsiness and sudden onset of sleep (see Driving); interactions: Appendix 1 (levodopa).", "side-effects": "Side-effects\u00a0\n(From Levodopa: British National Formulary)\nSide-effects\u00a0Side-effects of levodopa include nausea, vomiting, taste disturbances, dry mouth, anorexia, arrhythmias, palpitations, postural hypotension, syncope, drowsiness (see Driving), fatigue, dementia, psychosis, confusion, euphoria, abnormal dreams, insomnia, depression (very rarely with suicidal ideation), anxiety, dizziness, dystonia, dyskinesia, and chorea.Less commonly weight changes, constipation, diarrhoea, hypersalivation, dysphagia, flatulence, hypertension, chest pain, oedema, hoarseness, ataxia, hand tremor, malaise, weakness, muscle cramps, and reddish discoloration of the urine and other body fluids may occur. Rare side-effects include abdominal pain, gastro-intestinal bleeding, duodenal ulcer, dyspepsia, phlebitis, dyspnoea, agitation, paraesthesia, bruxism, trismus, hiccups, neuroleptic malignant syndrome (associated with abrupt withdrawal), convulsions, reduced mental acuity, disorientation, headache, urinary retention, urinary incontinence, priapism, activation of malignant melanoma, leucopenia, haemolytic and non-haemolytic anaemia, thrombocytopenia, agranulocytosis, blurred vision, blepharospasm, diplopia, activation of Horner\u2019s syndrome, pupil dilatation, oculogyric crisis, flushing, alopecia, exanthema, Henoch-Sch\u00f6nlein purpura, and sweating; very rarely angle-closure glaucoma may occur; compulsive behaviour (see Impulse Control Disorders) and false positive tests for urinary ketones have also been reported.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/10195.htm", "doses": ["Expressed as levodopa, initially 100\u00a0mg (with carbidopa\r\n25\u00a0mg) 3 times daily, increased by 50\u2013100\u00a0mg (with carbidopa 12.5\u201325\u00a0mg)\r\ndaily or on alternate days according to response, up to 800\u00a0mg (with\r\ncarbidopa 200\u00a0mg) daily in divided doses", "Alternatively, initially 50\u2013100\u00a0mg (with carbidopa 10\u201312.5\u00a0mg)\r\n3\u20134 times daily, increased by 50\u2013100\u00a0mg daily or on alternate days\r\naccording to response, up to 800\u00a0mg (with carbidopa 80\u2013100\u00a0mg) daily\r\nin divided doses ", "Alternatively, initially 125\u00a0mg (with carbidopa 12.5\u00a0mg, as\r\n\u00bd tablet of co-careldopa 25/250) 1\u20132 times daily, increased by 125\u00a0mg\r\n(with carbidopa 12.5\u00a0mg) daily or on alternate days according to response", "When co-careldopa is used, the total daily dose of carbidopa\r\nshould be at least 70\u00a0mg. A lower dose may not achieve full inhibition\r\nof extracerebral dopa-decarboxylase, with a resultant\r\nincrease in side-effects.", "When transferring patients\r\nfrom another levodopa/dopa-decarboxylase inhibitor preparation, the\r\nprevious preparation should be discontinued at least 12 hours before"], "pregnancy": "Pregnancy\u00a0\n(From Levodopa: British National Formulary)\nPregnancy\u00a0Levodopa should be used with caution in pregnancy\u2014toxicity has occurred in animal studies.Breast-feeding\u00a0Levodopa may suppress lactation. It is present in milk\u2014avoid."}, {"indications": "Indications\u00a0Parkinson\u2019s\r\ndisease, \n(From Levodopa: British National Formulary)\nLevodopa", "name": "CO-CARELDOPA With entacapone", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.9 Drugs used in parkinsonism and related disorders", "4.9.1 Dopaminergic drugs used in Parkinson\u2019s disease", "Levodopa", "CO-CARELDOPA", "With entacapone"], "cautions": "Cautions\u00a0\n(From Levodopa: British National Formulary)\nCautions\u00a0Levodopa should be used with caution in severe pulmonary or cardiovascular disease (including history of myocardial infarction with residual arrhythmia), psychiatric illness (avoid if severe and discontinue if deterioration), endocrine disorders (including hyperthyroidism, Cushing\u2019s syndrome, diabetes mellitus, osteomalacia, and phaeochromocytoma), and in those with a history of convulsions or peptic ulcer. Levodopa should be used with caution in patients susceptible to angle-closure glaucoma, and in hepatic or renal impairment. Patients should be advised to avoid abrupt withdrawal (risk of neuroleptic malignant syndrome and rhabdomyolysis), and to be aware of the potential for excessive drowsiness and sudden onset of sleep (see Driving); interactions: Appendix 1 (levodopa).", "side-effects": "Side-effects\u00a0\n(From Levodopa: British National Formulary)\nSide-effects\u00a0Side-effects of levodopa include nausea, vomiting, taste disturbances, dry mouth, anorexia, arrhythmias, palpitations, postural hypotension, syncope, drowsiness (see Driving), fatigue, dementia, psychosis, confusion, euphoria, abnormal dreams, insomnia, depression (very rarely with suicidal ideation), anxiety, dizziness, dystonia, dyskinesia, and chorea.Less commonly weight changes, constipation, diarrhoea, hypersalivation, dysphagia, flatulence, hypertension, chest pain, oedema, hoarseness, ataxia, hand tremor, malaise, weakness, muscle cramps, and reddish discoloration of the urine and other body fluids may occur. Rare side-effects include abdominal pain, gastro-intestinal bleeding, duodenal ulcer, dyspepsia, phlebitis, dyspnoea, agitation, paraesthesia, bruxism, trismus, hiccups, neuroleptic malignant syndrome (associated with abrupt withdrawal), convulsions, reduced mental acuity, disorientation, headache, urinary retention, urinary incontinence, priapism, activation of malignant melanoma, leucopenia, haemolytic and non-haemolytic anaemia, thrombocytopenia, agranulocytosis, blurred vision, blepharospasm, diplopia, activation of Horner\u2019s syndrome, pupil dilatation, oculogyric crisis, flushing, alopecia, exanthema, Henoch-Sch\u00f6nlein purpura, and sweating; very rarely angle-closure glaucoma may occur; compulsive behaviour (see Impulse Control Disorders) and false positive tests for urinary ketones have also been reported.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/128294.htm", "doses": ["Expressed as levodopa, initially 100\u00a0mg (with carbidopa\r\n25\u00a0mg) 3 times daily, increased by 50\u2013100\u00a0mg (with carbidopa 12.5\u201325\u00a0mg)\r\ndaily or on alternate days according to response, up to 800\u00a0mg (with\r\ncarbidopa 200\u00a0mg) daily in divided doses", "Alternatively, initially 50\u2013100\u00a0mg (with carbidopa 10\u201312.5\u00a0mg)\r\n3\u20134 times daily, increased by 50\u2013100\u00a0mg daily or on alternate days\r\naccording to response, up to 800\u00a0mg (with carbidopa 80\u2013100\u00a0mg) daily\r\nin divided doses ", "Alternatively, initially 125\u00a0mg (with carbidopa 12.5\u00a0mg, as\r\n\u00bd tablet of co-careldopa 25/250) 1\u20132 times daily, increased by 125\u00a0mg\r\n(with carbidopa 12.5\u00a0mg) daily or on alternate days according to response", "When co-careldopa is used, the total daily dose of carbidopa\r\nshould be at least 70\u00a0mg. A lower dose may not achieve full inhibition\r\nof extracerebral dopa-decarboxylase, with a resultant\r\nincrease in side-effects.", "When transferring patients\r\nfrom another levodopa/dopa-decarboxylase inhibitor preparation, the\r\nprevious preparation should be discontinued at least 12 hours before", "only 1 tablet to be taken for each dose; max. 10 tablets\r\ndaily", "only 1 tablet to be taken for each dose; max. 10 tablets\r\ndaily", "only 1 tablet to be taken for each dose; max. 7 tablets\r\ndaily", "Name[Stalevo\u00ae (Orion) ] Tablets, f/c, brown, levodopa 50\u00a0mg,\r\ncarbidopa 12.5\u00a0mg, entacapone 200\u00a0mg, net price 30-tab pack = \u00a320.79,\r\n100-tab pack = \u00a369.31. \r\n    Label:\r\n    10, 14 (urine\r\nreddish-brown), 25, counselling, driving, see notes aboveDose\u00a0only 1 tablet to be taken for each dose; max. 10 tablets\r\ndaily\nTablets, f/c, brown, levodopa 75\u00a0mg,\r\ncarbidopa 18.75\u00a0mg, entacapone 200\u00a0mg, net price 30-tab pack = \u00a320.79,\r\n100-tab pack = \u00a369.31. \r\n    Label:\r\n    10, 14 (urine\r\nreddish-brown), 25, counselling, driving, see notes aboveDose\u00a0only 1 tablet to be taken for each dose; max. 10 tablets\r\ndaily\nTablets, f/c, brown, levodopa 100\u00a0mg,\r\ncarbidopa 25\u00a0mg, entacapone 200\u00a0mg, net price 30-tab pack = \u00a320.79,\r\n100-tab pack = \u00a369.31. \r\n    Label:\r\n    10, 14 (urine\r\nreddish-brown), 25, counselling, driving, see notes aboveDose\u00a0only 1 tablet to be taken for each dose; max. 10 tablets\r\ndaily\nTablets, f/c, brown, levodopa 125\u00a0mg,\r\ncarbidopa 31.25\u00a0mg, entacapone 200\u00a0mg, net price 30-tab pack = \u00a320.79,\r\n100-tab pack = \u00a369.31. \r\n    Label:\r\n    10, 14 (urine\r\nreddish-brown), 25, counselling, driving, see notes aboveDose\u00a0only 1 tablet to be taken for each dose; max. 10 tablets\r\ndaily\nTablets, f/c, brown, levodopa 150\u00a0mg,\r\ncarbidopa 37.5\u00a0mg, entacapone 200\u00a0mg, net price 30-tab pack = \u00a320.79,\r\n100-tab pack = \u00a369.31. \r\n    Label:\r\n    10, 14 (urine\r\nreddish-brown), 25, counselling, driving, see notes aboveDose\u00a0only 1 tablet to be taken for each dose; max. 10 tablets\r\ndaily\nTablets, f/c, brown, levodopa 200\u00a0mg,\r\ncarbidopa 50\u00a0mg, entacapone 200\u00a0mg, net price 30-tab pack = \u00a320.79,\r\n100-tab pack = \u00a369.31. \r\n    Label:\r\n    10, 14 (urine\r\nreddish-brown), 25, counselling, driving, see notes aboveDose\u00a0only 1 tablet to be taken for each dose; max. 7 tablets\r\ndailyNote\u00a0Patients receiving standard-release co-careldopa\r\nor co-beneldopa alone, initiate Stalevo\u00ae at a dose\r\nthat provides similar (or slightly lower) amount of levodopaPatients with dyskinesia or receiving more than 800\u00a0mg levodopa\r\ndaily, introduce entacapone before transferring to Stalevo\u00ae (levodopa dose may need to be reduced by 10\u201330% initially)Patients receiving entacapone and standard-release co-careldopa\r\nor co-beneldopa, initiate Stalevo\u00ae at a dose that\r\nprovides similar (or slightly higher) amount of levodopa"], "pregnancy": "Pregnancy\u00a0\n(From Levodopa: British National Formulary)\nPregnancy\u00a0Levodopa should be used with caution in pregnancy\u2014toxicity has occurred in animal studies.Breast-feeding\u00a0Levodopa may suppress lactation. It is present in milk\u2014avoid."}, {"indications": "Indications\u00a0Parkinson\u2019s\r\ndisease, \n(From Levodopa: British National Formulary)\nLevodopa", "name": "CO-CARELDOPA Modified release", "breadcrumbs": ["Home", "BNF No. 63 (March 2012)", "4 Central nervous system", "4.9 Drugs used in parkinsonism and related disorders", "4.9.1 Dopaminergic drugs used in Parkinson\u2019s disease", "Levodopa", "CO-CARELDOPA", "Modified release"], "cautions": "Cautions\u00a0\n(From Levodopa: British National Formulary)\nCautions\u00a0Levodopa should be used with caution in severe pulmonary or cardiovascular disease (including history of myocardial infarction with residual arrhythmia), psychiatric illness (avoid if severe and discontinue if deterioration), endocrine disorders (including hyperthyroidism, Cushing\u2019s syndrome, diabetes mellitus, osteomalacia, and phaeochromocytoma), and in those with a history of convulsions or peptic ulcer. Levodopa should be used with caution in patients susceptible to angle-closure glaucoma, and in hepatic or renal impairment. Patients should be advised to avoid abrupt withdrawal (risk of neuroleptic malignant syndrome and rhabdomyolysis), and to be aware of the potential for excessive drowsiness and sudden onset of sleep (see Driving); interactions: Appendix 1 (levodopa).", "side-effects": "Side-effects\u00a0\n(From Levodopa: British National Formulary)\nSide-effects\u00a0Side-effects of levodopa include nausea, vomiting, taste disturbances, dry mouth, anorexia, arrhythmias, palpitations, postural hypotension, syncope, drowsiness (see Driving), fatigue, dementia, psychosis, confusion, euphoria, abnormal dreams, insomnia, depression (very rarely with suicidal ideation), anxiety, dizziness, dystonia, dyskinesia, and chorea.Less commonly weight changes, constipation, diarrhoea, hypersalivation, dysphagia, flatulence, hypertension, chest pain, oedema, hoarseness, ataxia, hand tremor, malaise, weakness, muscle cramps, and reddish discoloration of the urine and other body fluids may occur. Rare side-effects include abdominal pain, gastro-intestinal bleeding, duodenal ulcer, dyspepsia, phlebitis, dyspnoea, agitation, paraesthesia, bruxism, trismus, hiccups, neuroleptic malignant syndrome (associated with abrupt withdrawal), convulsions, reduced mental acuity, disorientation, headache, urinary retention, urinary incontinence, priapism, activation of malignant melanoma, leucopenia, haemolytic and non-haemolytic anaemia, thrombocytopenia, agranulocytosis, blurred vision, blepharospasm, diplopia, activation of Horner\u2019s syndrome, pupil dilatation, oculogyric crisis, flushing, alopecia, exanthema, Henoch-Sch\u00f6nlein purpura, and sweating; very rarely angle-closure glaucoma may occur; compulsive behaviour (see Impulse Control Disorders) and false positive tests for urinary ketones have also been reported.", "fname": "/home/david/src/nhshackday/bnf-html/www.medicinescomplete.com/mc/bnf/current/3643.htm", "doses": ["Expressed as levodopa, initially 100\u00a0mg (with carbidopa\r\n25\u00a0mg) 3 times daily, increased by 50\u2013100\u00a0mg (with carbidopa 12.5\u201325\u00a0mg)\r\ndaily or on alternate days according to response, up to 800\u00a0mg (with\r\ncarbidopa 200\u00a0mg) daily in divided doses", "Alternatively, initially 50\u2013100\u00a0mg (with carbidopa 10\u201312.5\u00a0mg)\r\n3\u20134 times daily, increased by 50\u2013100\u00a0mg daily or on alternate days\r\naccording to response, up to 800\u00a0mg (with carbidopa 80\u2013100\u00a0mg) daily\r\nin divided doses ", "Alternatively, initially 125\u00a0mg (with carbidopa 12.5\u00a0mg, as\r\n\u00bd tablet of co-careldopa 25/250) 1\u20132 times daily, increased by 125\u00a0mg\r\n(with carbidopa 12.5\u00a0mg) daily or on alternate days according to response", "When co-careldopa is used, the total daily dose of carbidopa\r\nshould be at least 70\u00a0mg. A lower dose may not achieve full inhibition\r\nof extracerebral dopa-decarboxylase, with a resultant\r\nincrease in side-effects.", "When transferring patients\r\nfrom another levodopa/dopa-decarboxylase inhibitor preparation, the\r\nprevious preparation should be discontinued at least 12 hours before", "Patients transferring from immediate-release levodopa/dopa-decarboxylase\r\ninhibitor preparations, 1 Sinemet\u00ae CR tablet twice daily can be substituted for a daily dose of levodopa 300\u2013400\u00a0mg in immediate-release Sinemet\u00ae tablets (substitute Sinemet\u00ae CR to provide approx. 10% more levodopa per day and extend dosing interval\r\nby 30\u201350%); dose and interval then adjusted according to response\r\nat intervals of not less than 3 days", "Name[Sinemet\u00ae CR (MSD) ] Tablets, m/r, peach, scored, co-careldopa 50/200 (carbidopa 50\u00a0mg (anhydrous), levodopa 200\u00a0mg), net price 60-tab pack = \u00a311.60. \r\n    Label:\r\n    10, 14, 25, counselling, driving, see notes aboveDose\u00a0patients not receiving levodopa/dopa-decarboxylase inhibitor\r\ntherapy, initially, 1 Sinemet\u00ae CR tablet twice daily; both dose and interval then adjusted according\r\nto response at intervals of not less than 3 daysPatients transferring from immediate-release levodopa/dopa-decarboxylase\r\ninhibitor preparations, 1 Sinemet\u00ae CR tablet twice daily can be substituted for a daily dose of levodopa 300\u2013400\u00a0mg in immediate-release Sinemet\u00ae tablets (substitute Sinemet\u00ae CR to provide approx. 10% more levodopa per day and extend dosing interval\r\nby 30\u201350%); dose and interval then adjusted according to response\r\nat intervals of not less than 3 days"], "pregnancy": "Pregnancy\u00a0\n(From Levodopa: British National Formulary)\nPregnancy\u00a0Levodopa should be used with caution in pregnancy\u2014toxicity has occurred in animal studies.Breast-feeding\u00a0Levodopa may suppress lactation. It is present in milk\u2014avoid."}]